Physician profile
Mark Matthew Doyle
NPI 1336460823
$1,596.13
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $301 · 2021: $1,034 · 2024: $20.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $285.53 | 2019-2021 | |
| Glaxosmithkline, LLC. | $261.67 | 2019-2021 | |
| Abbvie INC. | $211.66 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $118.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.32 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.48 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $100.93 | 2019-2021 | |
| Pfizer INC. | $89.56 | 2019-2021 | |
| Lilly USA, LLC | $41.71 | 2021 | |
| Currax Pharmaceuticals LLC | $39.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.94 | 2019-2021 | |
| Amarin Pharma, INC. | $36.57 | 2021 | |
| Ibsa Pharma INC. | $29.68 | 2020 | |
| Eisai INC. | $25.24 | 2021 | |
| Astellas Pharma US INC | $23.94 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $17.23 | 2021 | |
| Alfasigma USA, INC. | $16.85 | 2021 | |
| Amgen INC. | $16.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2021 | |
| Allergan, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.